Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes
Phase 3positivesurvodutidePositive
AI Analysis
Summary
Boehringer Ingelheim announced positive Phase III SYNCHRONIZE-2 results for survodutide, achieving 13.1% average weight loss and ≥5% weight reduction in 79.3% of patients with obesity and type 2 diabetes, significantly outperforming placebo.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Met co-primary endpoints: 13.1% average weight loss versus 3.1% placebo (p<0.0001); 79.3% achieved ≥5% weight reduction versus 32.7% placebo (p<0.0001); significant glycemic control improvements
Importance:8/10
Sentiment:
0.95
Phase 3obesitytype 2 diabetesweight lossGLP-1 agonistglucagon receptor agonistEASD 2026
Related Companies
Read the original article
Published by GlobeNewswire Pharma on October 1, 2026 7:30 AM